Siemens Healthineers Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Bernd Montag

Algemeen directeur

€5.7m

Totale compensatie

Percentage CEO-salaris	24.1%
Dienstverband CEO	9.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Bernd Montag's beloning veranderd ten opzichte van Siemens Healthineers's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	€2b
Jun 30 2024	n/a	n/a	€2b
Mar 31 2024	n/a	n/a	€2b
Dec 31 2023	n/a	n/a	€2b
Sep 30 2023	€6m	€1m	€2b
Jun 30 2023	n/a	n/a	€2b
Mar 31 2023	n/a	n/a	€2b
Dec 31 2022	n/a	n/a	€2b
Sep 30 2022	€6m	€1m	€2b
Jun 30 2022	n/a	n/a	€2b
Mar 31 2022	n/a	n/a	€2b
Dec 31 2021	n/a	n/a	€2b
Sep 30 2021	€5m	€1m	€2b
Jun 30 2021	n/a	n/a	€2b
Mar 31 2021	n/a	n/a	€2b
Dec 31 2020	n/a	n/a	€2b
Sep 30 2020	€4m	€1m	€1b
Jun 30 2020	n/a	n/a	€1b
Mar 31 2020	n/a	n/a	€2b
Dec 31 2019	n/a	n/a	€2b
Sep 30 2019	€4m	€1m	€2b
Jun 30 2019	n/a	n/a	€1b
Mar 31 2019	n/a	n/a	€1b
Dec 31 2018	n/a	n/a	€1b
Sep 30 2018	€3m	€613k	€1b

Compensatie versus markt: De totale vergoeding ($USD 6.02M ) Bernd } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 5.70M ).

Compensatie versus inkomsten: De vergoeding van Bernd is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Bernd Montag (55 yo)

9.8yrs

Tenure

€5,717,000

Compensatie

Dr. Bernhard Montag, also known as Bernd, serves as President and at Chairman of Management Board at Siemens Healthineers AG. He has been Chief Executive Officer at Siemens Healthineers AG since 2015 and s...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Bernhard Montag	President	9.8yrs	€5.72m	geen gegevens
Jochen Schmitz	CFO & Member of Management Board	6.9yrs	€2.94m	geen gegevens
Darleen Caron	Chief Human Resources Officer	3.8yrs	€2.56m	geen gegevens
Elisabeth Staudinger-Leibrecht	Member of Management Board	2.9yrs	€2.47m	geen gegevens
Marc Koebernick	Head of Investor Relations	no data	geen gegevens	geen gegevens
Christian Klaussner	Executive Vice President of Finance	no data	geen gegevens	geen gegevens
Andre Hartung	Head of Imaging	3.8yrs	geen gegevens	geen gegevens
Carsten Bertram	Head of Advanced Therapies	3.8yrs	geen gegevens	geen gegevens
David Pacitti	Head of Americas	3.8yrs	geen gegevens	geen gegevens
Sharon Bracken	Head of Diagnostics	2.5yrs	geen gegevens	geen gegevens
Jerry Wang	Head of China	2.8yrs	geen gegevens	geen gegevens
Vy Tran	Head of Asia Pacific Japan	2.8yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0PMJ wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peer Schatz	Independent Member of Supervisory Board	3.7yrs	€229.67k	geen gegevens
Dow Wilson	Independent Member of Supervisory Board	1.8yrs	€133.08k	geen gegevens
Karl-Heinz Streibich	Independent Deputy Chairman of Supervisory Board	6.7yrs	€238.75k	geen gegevens
Ralf Peter Thomas	Chairman of Supervisory Board	6.7yrs	geen gegevens	geen gegevens
Marion Helmes	Independent Member of Supervisory Board	6.7yrs	€248.83k	geen gegevens
Roland Busch	Member of Supervisory Board	4.8yrs	geen gegevens	geen gegevens
Sarena Lin	Independent Member of Supervisory Board	1.8yrs	€118.83k	geen gegevens
Nathalie von Siemens	Independent Member of Supervisory Board	6.7yrs	€161.75k	geen gegevens
Veronika Bienert	Member of Supervisory Board	1.8yrs	€132.33k	geen gegevens
Peter Korte	Member of Supervisory Board	1.8yrs	€151.00k	geen gegevens

4.2yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0PMJ wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Siemens Healthineers Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Siemens Healthineers AG Appoints Vivek Kanade as Head of Middle East and Africa

Siemens Healthineers AG, Annual General Meeting, Apr 18, 2024

Siemens Healthineers AG, Annual General Meeting, Feb 15, 2023

Recent updates

New major risk - Financial position

Full year 2024 earnings released: EPS: €1.74 (vs €1.35 in FY 2023)

Siemens Healthineers AG to Report Fiscal Year 2024 Results on Nov 26, 2024

Siemens Healthineers Offers to Buy Novartis Molecular Imaging Business

Second quarter 2024 earnings released: EPS: €0.38 (vs €0.09 in 2Q 2023)

Upcoming dividend of €0.95 per share

First quarter 2024 earnings released: EPS: €0.39 (vs €0.38 in 1Q 2023)

Siemens Healthineers AG Appoints Vivek Kanade as Head of Middle East and Africa

Siemens Healthineers AG, Annual General Meeting, Apr 18, 2024

Full year 2023 earnings released: EPS: €1.35 (vs €1.82 in FY 2022)

Siemens Healthineers AG to Report Fiscal Year 2023 Final Results on Nov 27, 2023

Siemens Healthineers AG to Report Q2, 2024 Results on May 06, 2024

Siemens Healthineers AG to Report Q1, 2024 Results on Feb 01, 2024

Third quarter 2023 earnings released: EPS: €0.40 (vs €0.32 in 3Q 2022)

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Now 20% undervalued

Second quarter 2023 earnings released: EPS: €0.093 (vs €0.52 in 2Q 2022)

Upcoming dividend of €0.95 per share at 1.8% yield

First quarter 2023 earnings released: EPS: €0.38 (vs €0.41 in 1Q 2022)

Siemens Healthineers AG to Report Q1, 2023 Results on Feb 02, 2023

Siemens Healthineers, GE Healthcare Studying Potential Deals with Medtronic's Spun Off Units

Siemens Healthineers AG to Report Q2, 2023 Results on May 10, 2023

Siemens Healthineers AG, Annual General Meeting, Feb 15, 2023

Now 20% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Now 22% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: €0.52 (vs €0.41 in 2Q 2021)

Upcoming dividend of €0.85 per share

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Siemens Healthineers Launches Enhanced Liver Fibrosis (ELF) Test in the U.S

Siemens Healthineers Announces FDA Emergency Use Authorization For CLINITEST® Rapid COVID-19 Antigen Self-Test

Full year 2021 earnings released: EPS €1.57 (vs €1.41 in FY 2020)

FDA Grants Marketing Authorization to Siemens Healthineers's ELF Test for NASH Prognostic Assessment

Second quarter 2021 earnings released: EPS €0.41 (vs €0.41 in 2Q 2020)

Upcoming Dividend of €0.80 Per Share

New 90-day high: €44.37

New 90-day high: €42.35

Renown Institute for Health Innovation Expands Partnership with Gilead Sciences, Inc. and Siemens Healthineers to Offer ELF- Enhanced Liver Fibrosis Testing for Nevada Nash Study Participants

New 90-day high: €39.83

Siemens Healthineers AG to Report Q1, 2021 Results on Feb 01, 2021

Revenue misses expectations

Full year 2020 earnings released: EPS €1.41

Revenue misses expectations

Full year 2020 earnings released: EPS €1.41

Siemens Healthineers and University of Iowa Health Care Team Up to Advance Care for Iowans Over the Next Decade

Siemens Healthineers and WakeMed Health & Hospitals Announce Innovative Relationship to Advance Care and Improve Outcomes

Siemens Healthineers Announces Collaboration Agreement for Assay Development with an Initial Focus on Multiple Sclerosis

Siemens Healthineers AG has completed a Follow-on Equity Offering in the amount of €2.73 billion.

New 90-day low - €39.62

New 90-day low - €40.02

Earnings released

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd